Maijatech

Maija Technology is a Shanghai-based biotechnology company specializing in AI-driven drug discovery with a primary focus on targeting protein-protein interactions (PPIs). The company utilizes its proprietary computational platform to identify and optimize small molecule candidates for traditionally "undruggable" targets. Maija Technology primarily operates in the fields of oncology and immunology, aiming to accelerate the development of first-in-class therapeutics. Its approach combines structural biology, machine learning, and physics-based simulations to address complex disease mechanisms. The firm has successfully raised significant seed and angel funding from prominent investors to advance its internal pipeline and platform capabilities.